Idorsia Aktie
2,80CHF | 0,01CHF | 0,36% |
WKN DE: A2DTEB / ISIN: CH0363463438
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 1 035 | 1 077 | 596 | 276 | 255 |
Summe Anlagevermögen | 401 | 405 | 308 | 224 | 250 |
Summe Aktiva | 1 435 | 1 483 | 904 | 500 | 506 |
Bilanz (in Mio. CHF) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 850 | 1 379 | 1 565 | 1 469 | 1 718 |
Summe Eigenkapital | 585 | 104 | -661 | -969 | -1 212 |
Summe Passiva | 1 435 | 1 483 | 904 | 500 | 506 |
Adresse
Hegenheimermattweg 91, 4123 Allschwil | |
Telefon | +41 (58) 844-10-10 |
Internet | http://www.idorsia.com |
Management
Alberto Gimona
Head-Global Clinical Development & Executive VP |
Andrew Jones
SVP, Head-Corporate Communications & IR |
Antonio Olivieri
Chief Medical Officer & Head-Global Medical Affair |
Arno Groenewoud
Chief Financial Officer & Executive Vice President |
Bart Filius
Non-Executive Director |
Gaby Scherer
Senior VP & Head-Global Human Resources |
Jean-Paul Clozel
Chairman |
Julien Gander
Chief Legal & Corporate Development Officer, EVP |
Martine Clozel
Chief Scientific Officer, EVP & Head-Research |
Mathieu Simon
Vice Chairman |
Olivier Lambert
Senior Vice President & Head-Technical Operations |
Sandesh Mahatme
Non-Executive Director |
Srishti Gupta
Chief Executive Officer & Director |